Israel state records י"ב באדר התשס"ו March 12, 2006



Download 0.86 Mb.
Page12/13
Date06.06.2017
Size0.86 Mb.
#20054
1   ...   5   6   7   8   9   10   11   12   13

[57] Use of a compound having NMDA receptor antagonist activity wherein the compound is selected from the group consisting of a compound of the formula



where: R1 and R2 are independently phenyl or 4-fluorophenyl;

R3 is hydrogen, C1-6 alkyl or methoxycarbonyl;



R4 is hydrogen or methyl; and metabolites and isomers thereof both as a free base and pharmaceutically acceptable salts thereof; memantine, alpha-phenyl,-1H-pyrazole-1-ethanamine, (+)-N-ethyl-1-phenyl-2-(3-pyrazine) ethanamine, 2-amidino-6-(2-amino-2-phenyl)-ethylpyridine trihydrochloride, 2,3-diphenyl-2-propylamine, (S)-1-phenyl-2-(2-pyridyl)ethanamine or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS).

__________



139275

[21][11]

התקן מערך אלקטרודות מוקטן ושיטה לזיהוי תנאיי איסכמיה לבבית חריפים


REDUCED LEAD SET DEVICE AND METHOD FOR DETECTING ACUTE CARDIAC ISCHEMIC CONDITIONS


[54]




29.04.1999

[22]




US

[33]

30.04.1998

[32]

60/083722

[31]




US




15.09.1998




60/100391







US




11.12.1998




209879







US




13.01.1999




229977




Int. Cl.7 A61B 005/00, 005/0452

[51]




MEDTRONIC PHYSIO-CONTROL MANUFACTURING CORP., U.S.A.

[71]




WO/1999/055228

[87]

ריינהולד כהן ושותפיו,

רחוב אחד העם 21 , ת.ד. 4060, תל אביב



REINHOLD COHN AND PARTNERS,

21 AHAD HA'AM ST.,

P.O.BOX 4060,

TEL AVIV 61040



[74]










[57] A reduced lead set device (10) for detecting and reporting a condition associated with acute cardiac ischemia in a patient, comprising:

(a) a reduced set of electrodes (12-18) for sensing ECG signals of the patient, wherein the reduced set of electrodes includes less than ten electrodes;

(b) a processing unit in communication with the reduced set of electrodes, the processing unit configured to:

(i) derive a reduced set of lead data from the ECG signals;

(ii) calculate features from the reduced set of lead data; and

(iii) classify the features to determine whether the patient has an acute care ischemic or non-ischemic condition; and

(c) a user output in communication with the processing unit for directly reporting to a user of the reduced lead set device whether the patient's cardiac condition was determined ischemic.



__________





139277

[21][11]

שיטה ליצור איזוקסאזולין-3 אציל בנזן


METHOD FOR PRODUCING ISOXAZOLINE-3-YL ACYL BENZENE


[54]




04.05.1999

[22]




DE

[33]

11.05.1998

[32]

19820722.0

[31]




DE




12.11.1998




19852095.6




Int. Cl.7 C07C 251/40, 319/14, C07D 261/04, 413/10

[51]




BASF AKTIENGESELLSCHAFT, GERMANY

[71]




WO/1999/058509

[87]

ריינהולד כהן ושותפיו,

רחוב אחד העם 21 , ת.ד. 4060, תל אביב



REINHOLD COHN AND PARTNERS,

21 AHAD HA'AM ST.,

P.O.BOX 4060,

TEL AVIV 61040



[74]




[57] A process for preparing isoxazoles of the formula




where the substituents are as defined below:

R1 is hydrogen, C1-C6-alkyl,

R2 is C1-C6-alkyl,

R3, R4, R5 are hydrogen, C1-C6-alkyl, or R4 and R5 together form a bond,

R6 is a heterocyclic ring,

n is 0, 1 or 2; which comprises preparing an intermediate of the formula






where R1, R3, R4 and R5 are as defined above, and subsequent reaction to give compounds of the formula (I).

__________



139369

[21][11]

שיטה לריווי–על עבור אמצעי תקשורת בתחום המידע


SUPER SATURATION METHOD FOR INFORMATION MEDIA


[54]




30.10.2000

[22]

Int. Cl.7 G06F 01760

[51]




ALMONDNET, INC., U.S.A.

[71]

01פטנטים בע"מ,

יזראל 1 , ת.ד. 28051, ירושלים



01PATENTS LTD,

1 YIZREEL STREET P.O. BOX 28051 JERUSALEM



[74]




[57] A super-saturation method for information-media, whereby a second information-media broadcaster in conjunction with an agency extends a content presentation of a first broadcaster beyond a predetermined information-media saturation threshold for content presentation of the first broadcaster, the method including the steps of:

(a) facilitating visitor identification by an agency;

(b) tagging, by a first broadcaster of a first information-media in conjunction with the agency, a preponderance of visitors to the first information-media with a tag;

(c) recognizing, by a second broadcaster of a second information-media in conjunction with the agency, a visitor to the second information-media as having the tag;

(d) accepting, by the second broadcaster in conjunction with either the agency or the first broadcaster, an offsite content presentation for the recognized visitor; and

(e) presenting the offsite content to the recognized visitor.


__________



139590

[21][11]

ייצוב של תכשירים יציבים המכילים מעכבים של ACE על ידי שימוש במגנזיום אוקסיד


STABILIZATION OF COMPOSITIONS CONTAINING ACE INHIBITORS USING MAGNESIUM OXIDE


[54]




10.05.1999

[22]




US

[33]

05.06.1998

[32]

60/088280

[31]

Int. Cl.7 A61K 047/00

[51]




WARNER-LAMBERT COMPANY LLC, U.S.A.

[71]




WO/1999/062560

[87]

לוצאטו את לוצאטו,

גן תעשיה, עומר , ת.ד. 5352, באר שבע



LUZZATTO & LUZZATTO,

P.O.B. 5352

BEER-SHEVA 84965


[74]




[57] A pharmaceutical composition which contains: (a) a compound of the formula





wherein A is absent, a fused 5-, 6-, or 7-membered cycloalophatic ring or a fused benzene ring which is unsubstituted or substituted by 1 or 2 alkoxy groups having 1 to 4 carbon atoms; n is 0 or 1, and R is hydrogen or alkyl having 1 to 5 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof; (b) a suitable amount of a stabilizer to retard cyclization and discoloration, the stabilizer consisting of magnesium oxide; and (c) a suitable amount of a saccharide to inhibit hydrolysis.

__________





139635

[21][11]

נגזרות ואנלוגים חדשים של חומצה 3 – אריל פרופיונית, תכשירי רוקחותה מכילים אותם, ושימושם בהכנת תרופות לטיפול במצבים ובמחלות הקשורים לעמידות לאינסולין


3 - ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING INSULIN RESISTANCE RELATED CONDITIONS AND DISORDERS


[54]




31.05.1999

[22]




SE

[33]

04.06.1998

[32]

9801992-0

[31]




SE




04.06.1998




9801990-4







SE




04.06.1998




9801991-2




Int. Cl.7 A61K 031/10, 031/13, 031/16, 031/275, 031/325, 031/33, A61P 003/10, C07C 217/80, 233/25, 235/42, 255/54, 271/28, 275/34, 309/24, 309/29, 309/41, 309/63, 311/08, 317/22, 323/19, 335/18

[51]




ASTRAZENECA AB, SWEDEN

[71]




KJELL ANDERSSON, MARIA BOIJE,, JOHAN GOTTFRIES, INGHARDT TORD, LANNA LI, EVA-LOTTE LINDSTEDT ALSTERMARK

[72]




WO/1999/062871

[87]

לוצאטו את לוצאטו,

גן תעשיה, עומר , ת.ד. 5352, באר שבע



LUZZATTO & LUZZATTO,

P.O.B. 5352

BEER-SHEVA 84965


[74]




[57] A compound of the formula



and stereo- and optical isomers and racemates thereof as well as pharmaceutically acceptable salts, solvates and crystalline forms thereof, in which formula A is situated in the ortho, meta or para position and represents





R is hydrogen; -ORa, wherein Ra represents hydrogen, alkyl, aryl or alkylaryl; -NRaRb, wherein Ra and Rb are the same or different and Ra is as defined above and Rb represents hydrogen, alkyl, aryl, alkylaryl, cyano, -OH, -Oalkyl, Oaryl,-Oalkylaryl, -CORc or –SOsRd, wherein Rc represents hydrogen, alkyl, aryl or alkylaryl and Rd represents alkyl, aryl or alkylaryl;

R1 is alkyl, aryl, alkenyl, alkynyl, cyano;

-ORe, wherein Re is alkyl, acyl, aryl or alkylaryl;

-O-[CH2]m-ORf, wherein Rf represents hydrogen, alkyl, acyl, aryl or alkylaryl and m represents an integer 1-8;

-OCONRaRc, wherein Ra and Rc are as defined above;

-SRd, wherein Rd is as defined above:

-SO2NRaRf, wherein Rf and Ra are as defined above;

-SOsORa, wherein Ra is as defined above;

-COORd, wherein Rd is as defined above;

R2 is hydrogen, halogen, alkyl, aryl, or alkylaryl,

R3 and R4 are the same or different and each represents hydrogen, alkyl, aryl, or alkylaryl,

n is an integer 1-6,

D is situated in the ortho, meta or para position and represents –OSO2Rd, wherein Rd is as defined above;

-OCONRfRa, wherein Rf and Ra are as defined above;

-NRcCORa, wherein Rc and Ra are as defined above;

-NRcRd, wherein Rc and Rd are as defined above;

-NRcSO2Rd, wherein Rc and Rd are as defined above;

-NRcCONRaRk, wherein Ra, Rc and Rk are the same or different and each represents hydrogen, alkyl, aryl, or alkylaryl;

-NRcCSNRaRk, wherein Ra, Rc and Rk are the same or different and each represents hydrogen, alkyl, aryl or alkyaryl;

-SO2Rd, wherein Rd is as defined above;

-SORd, wherein Rd is as defined above;

-SRc, wherein Rc is as defined above;

-SO2NRaRf, wherein Rf and Ra are as defined above;

-SO2ORa, wherein Ra is as defined above;

-CN, -CONRcRa, wherein Rc and Ra are as defined above;

D' is situated in the ortho, meta or para position and represents hydrogen, alkyl, acyl, aryl, alkyaryl, halogen, -CN, -NO2, -NRfRb, wherein Rf and Rb are as defined above;

-ORf, wherein Rf is as defined above;

-OSO2Rd, wherein Rd is as defined above;

D'' is situated in the ortho, meta or para position and represents hydrogen, alkyl, acyl, aryl, alkyaryl, halogen, -CN, -NO2, -NRfRb wherein Rf and Rb are as defined above;

-ORf, wherein Rf is as defined above,

-OSO2Rd, wherein Rd is as defined above, wherein the term "aryl" denotes a substituted or unsubstituted phenyl, furyl, thienyl or pyridyl group, or naphthyl;

wherein the term "alkyl" denotes a straight or branched, substituted or unsubstituted alkyl group having from 1 to 6 carbon atoms or a cyclic alkyl having from 3 to 6 carbon atoms and wherein the term "substituted" denotes an alkyl or an aryl group as defined above which is substituted by one or more alkyl, alkoxy, halogen, amino, thiol, nitro, hydroxy, acyl, aryl or cyano groups;

with the exception of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)

phenyl] propanoic acid, and 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy] phenyl}-(S)-2-ethoxypropanoic acid.


__________





139638

[21][11]

התגרענות וגדילה של חלקיקים זעירים של תחמוצת מתכתית מגנטית ושימושיהם


NUCLEATION AND GROWTH OF MAGNETIC METAL OXIDE NANOPARTICLES AND THEIR USE


[54]




24.05.1999

[22]




US

[33]

26.05.1998

[32]

09/084726

[31]

Int. Cl.7 A61K 049/00, B01J 013/08, H01F 001/00

[51]

אוניברסיטת בר אילן, רמת גן

BAR-ILAN UNIVERSITY

[71]




WO/1999/062079

[87]

לוצאטו את לוצאטו,

גן תעשיה, עומר , ת.ד. 5352, באר שבע



LUZZATTO & LUZZATTO,

P.O.B. 5352

BEER-SHEVA 84965


[74]





Download 0.86 Mb.

Share with your friends:
1   ...   5   6   7   8   9   10   11   12   13




The database is protected by copyright ©ininet.org 2024
send message

    Main page